Investors

Corporate News

Administration of NuPharm

26 April 2017

Quantum Pharma Plc (AIM: QP.), the service-led niche pharmaceutical developer, manufacturer and supplier, announces that following the cessation of trading at NuPharm Laboratories Limited ('NuPharm') in January, NuPharm was placed into administration earlier today. In accordance with paragraph (g) of Schedule 2 of the AIM Rules for Companies, Quantum confirms that Chris Rigg, CEO, was also a director of NuPharm when it was placed into administration.

 

For further information:

Quantum Pharma Plc  
Chris Rigg, Chief Executive Officer Tel: +44 (0) 1207 279 404
Gerard Murray, Chief Financial Officer  
ir@quantumpharma.co.uk www.quantumpharmagroup.com
   
N+1 Singer
(Nominated Advisor & Broker)
Tel: +44 (0) 20 7496 3000
Sandy Fraser / Nick Owen / James White www.n1singer.com
   
Media enquiries:  
Buchanan  
Henry Harrison-Topham Tel: +44 (0) 20 7466 5000
quantumpharma@buchanan.uk.com www.buchanan.uk.com

 

Notes to Editors

Quantum Pharma is a service-led, niche pharmaceutical developer, manufacturer and supplier to the retail pharmacy, pharmaceutical wholesale, hospital, homecare and care home markets. Quantum Pharma operates through three divisions - Specials, Niche Pharmaceuticals and Medication Adherence - offering a portfolio of innovative and complementary products and services.

For further information, please visit www.quantumpharmagroup.com.

 

back to top

back to Corporate News

 

 
Quantum Pharmaceuticals
UL Medicines
Quantum Aseptics
PERN Consumer Products
Biodose Intelligent Medication Management